Checkpoint Revolution: Navigating New Frontiers in Cancer Immunotherapy

Life Sciences, Clinical Trials, Pharmaceutical Regulation, Patient Recruitment & Retention, Drug Discovery & Development, Drug Safety, Biomarkers,
  • Thursday, January 25, 2024

Discover an informative webinar on checkpoint inhibitors in cancer immunotherapy, exploring immune checkpoint inhibitors (ICIs), The Food and Drug Administration (FDA)-approved therapies, combination treatments and strategies to predict patient responses in cancer treatment. Since their initial approval in 2011 for metastatic melanoma, ICIs have changed the treatment paradigm in oncology. To date, eight ICIs and 35 ICI-based combination immunotherapies have been approved by The FDA across diverse tumor types. First-line programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors have become increasingly common for the treatment of metastatic cancer, with significant survival benefits. Still, while a subset of patients exhibit deep, durable responses to these therapeutics, the majority do not respond to single-agent ICIs and many experience immune-related adverse events.

To improve the efficacy and safety of ICIs and advance the understanding of the molecular pathways that cause cancer resistance, it is crucial to find new, effective and tolerable combination treatments. In this webinar, the featured speakers will explore the latest advancements in ICI and discuss strategies for expanding the use of these novel therapeutics.

Join this webinar to discover insights shaping cancer treatment and learn about the impact of ICIs, patient responses and the future of ICI therapies.


Ayesha A. Pandit, Premier Research

Ayesha A. Pandit, MD, MS, MBA, Vice President, Oncology & Hematology Medical Affairs, Premier Research

Dr. Ayesha Pandit serves as the Vice President, Medical Affairs, for Premier Research. A board-certified Hemato-Oncologist, Dr. Pandit brings over 20 years of oncology experience from her tenure in world-leading companies, including AbbVie, Johnson & Johnson and MD Anderson Hospital. In her role at Premier, Dr. Pandit leads and supports the global strategy for hematology/oncology clinical trials and manages high-profile clinical programs within the oncology space.

Dr. Pandit earned her MD from King Edward Medical University in Pakistan, and her residency and fellowship from King’s College London in UK. Dr. Pandit also holds an MS in Molecular Oncology and an MBA in Healthcare Management from the National University of Singapore.

Message Presenter

Who Should Attend?

This webinar will benefit managers and above at biotech and specialty pharma companies with job functions including, but not limited, to:

  • Clinical operations
  • Medical affairs
  • Project management
  • Regulatory affairs

What You Will Learn

Attendees will gain insights into:

  • Introduction to ICIs, patient response, and survival benefits: A review of the latest statistics on FDA-approved ICIs, their combination therapies, and what’s new in the space
  • Challenges, limitations, and safety management: The latest research and guidelines on resistance mechanisms to ICIs, dosing optimization, and the management of immune-related adverse events
  • Patient selection and biomarkers: An introduction to new biomarkers for predicting ICI response and strategies for patient stratification
  • Future perspectives: Emerging areas such as the role of the microbiome in modulating ICI response and novel immune checkpoints under investigation

Xtalks Partner

Premier Research

Premier Research, a clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions. Visit

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account